• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by GeneDx Holdings Corp.

    8/14/25 12:33:25 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology
    Get the next $WGS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    GENEDX HOLDINGS CORP.

    (Name of Issuer)


    Class A common stock, par value $0.0001 per share

    (Title of Class of Securities)


    81663L200

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Summit Partners Public Asset Management, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    771,333.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    867,265.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    867,265.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox checked
    11Percent of class represented by amount in row (9)

    3.04 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Summit Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    771,333.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    771,333.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    771,333.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Summit Partners Concentrated Growth L/S Master Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    103,992.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    103,992.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    103,992.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.36 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Summit Partners Technology L/S Master Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    67,546.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    67,546.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    67,546.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    .24 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Summit Partners Sustainable Opportunities L/S Fund Limited
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    235,761.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    235,761.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    235,761.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    .83 %
    12Type of Reporting Person (See Instructions)

    CO


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Summit Partners Sustainable Opportunities L/S QP Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    353,762.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    353,762.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    353,762.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.24 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Summit Partners Sustainable Opportunities L/S Fund, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    10,272.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    10,272.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,272.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    .04 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Summit Partners Alydar GP, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    535,572.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    535,572.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    535,572.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.88 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Summit Partners Alydar GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    535,572.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    535,572.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    535,572.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.88 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Philip Furse
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    771,333.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    867,265.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    867,265.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox checked
    11Percent of class represented by amount in row (9)

    3.04 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Timothy Albright
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    771,333.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    867,265.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    867,265.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox checked
    11Percent of class represented by amount in row (9)

    3.04 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Robert MacAulay
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    771,333.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    867,265.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    867,265.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox checked
    11Percent of class represented by amount in row (9)

    3.04 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    81663L200


    1Names of Reporting Persons

    Matthew Curtis
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    771,333.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    867,265.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    867,265.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox checked
    11Percent of class represented by amount in row (9)

    3.04 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    GENEDX HOLDINGS CORP.
    (b)Address of issuer's principal executive offices:

    333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, 06902
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (each a "Reporting Person" and collectively, the "Reporting Persons") are: (i) Summit Partners Public Asset Management, LLC ("SPPAM"), (ii) Summit Partners, L.P. ("SP"), (iii) Summit Partners Concentrated Growth L/S Master Fund, L.P. ("Summit Concentrated Growth"), (iv) Summit Partners Technology L/S Master Fund, L.P. ("Summit Technology"), (v) Summit Partners Sustainable Opportunities L/S Fund Limited ("SPSO Limited"), (vi) Summit Partners Sustainable Opportunities L/S QP Fund, L.P. ("SPSO QP"), (vii) Summit Partners Sustainable Opportunities L/S Fund, L.P. ("SPSO LP"), (viii) Summit Partners Alydar GP, L.P. ("Fund GP"), (ix) Summit Partners Alydar GP, LLC ("GP"), (x) Philip Furse, (xi) Timothy Albright, (xii) Robert MacAulay and (xiii) Matthew Curtis. The Reporting Persons have entered into a Joint Filing Agreement, dated February 12, 2025, a copy of which is incorporated by reference as Exhibit A to this statement, pursuant to which the Reporting Persons agreed to file this Schedule 13G and any amendments hereto jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office or registered office, as applicable, of SPPAM, SP, SPSO QP, SPSO LP, Fund GP, GP, Philip Furse, Timothy Albright, Robert MacAulay and Matthew Curtis is 222 Berkeley Street, 18th Floor, Boston, MA 02116. The registered office address of Summit Concentrated Growth, Summit Technology and SPSO Limited is c/o Walkers Corporate Limited, 190 Elgin Avenue, George Town, Grand Cayman KY1-9008, Cayman Islands.
    (c)Citizenship:

    SPPAM, SP, SPSO QP, SPSO LP, Fund GP, and GP are organized under the laws of the State of Delaware. Philip Furse, Timothy Albright and Robert MacAulay are citizens of the United States. Summit Concentrated Growth and Summit Technology are each a Cayman Islands limited partnership. SPSO Limited is a Cayman Islands exempted company.
    (d)Title of class of securities:

    Class A common stock, par value $0.0001 per share
    (e)CUSIP No.:

    81663L200
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    867,265
    (b)Percent of class:

    3.04%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    771,333

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    867,265

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Summit Partners Public Asset Management, LLC
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, Authorized Person
    Date:08/14/2025
     
    Summit Partners, L.P.
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, Authorized Person
    Date:08/14/2025
     
    Summit Partners Concentrated Growth L/S Master Fund, L.P.
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, Authorized Person
    Date:08/14/2025
     
    Summit Partners Technology L/S Master Fund, L.P.
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, Authorized Person
    Date:08/14/2025
     
    Summit Partners Sustainable Opportunities L/S Fund Limited
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, Authorized Person
    Date:08/14/2025
     
    Summit Partners Sustainable Opportunities L/S QP Fund, L.P.
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, Authorized Person
    Date:08/14/2025
     
    Summit Partners Sustainable Opportunities L/S Fund, L.P.
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, Authorized Person
    Date:08/14/2025
     
    Summit Partners Alydar GP, L.P.
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, Authorized Person
    Date:08/14/2025
     
    Summit Partners Alydar GP, LLC
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, Authorized Person
    Date:08/14/2025
     
    Philip Furse
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, POA for Philip Furse
    Date:08/14/2025
     
    Timothy Albright
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, POA for Timothy Albright
    Date:08/14/2025
     
    Robert MacAulay
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, POA for Robert MacAulay
    Date:08/14/2025
     
    Matthew Curtis
     
    Signature:Adam H. Hennessey
    Name/Title:Adam H. Hennessey, POA for Matthew Curtis
    Date:08/14/2025
    Exhibit Information

    Item 4: The information required by Item 4 with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of each cover page to this Schedule 13G. The ownership percentages are calculated based on 28,553,204 outstanding shares of Common Stock, as of April 23, 2025, as reported in the issuer's Quarterly Report on Form 10-Q filed on April 30, 2025. SPPAM is the investment manager with respect to shares of Common Stock and call options to purchase shares of Common Stock ("Call Options") directly held by Summit Concentrated Growth, SPSO QP, SPSO LP, SPSO Limited and Summit Technology (collectively the "Funds") and a separately managed account. SP is the Managing Member of SPPAM. Summit Concentrated Growth, Summit Technology, and a separately managed account each directly hold shares of Common Stock. SPSO Limited, SPSO QP and SPSO LP each directly holds shares of Common Stock and Call Options. Fund GP is the general partner of Summit Concentrated Growth, SPSO QP, SPSO LP and Summit Technology. GP is the general partner of Fund GP. Philip Furse is the Chief Investment Officer of SPPAM and a Portfolio Manager of SPPAM, with respect to the shares of Common Stock and Call Options directly held by the Funds and the separately managed account of SPPAM. Timothy Albright is a Portfolio Manager of SPPAM with respect to the shares of Common Stock and Call Options directly held by the Funds and the separately managed account of SPPAM. Robert MacAulay is the Chief Risk Officer of SPPAM with respect to the shares of Common Stock and Call Options directly held by the Funds and the separately managed account of SPPAM. Matthew Curtis is a Portfolio Manager of SPPAM with respect to the shares of Common Stock and Call Options directly held by the Funds and the separately managed account of SPPAM. Accordingly, each of the Reporting Persons may be deemed the beneficial owner of the reported securities but the filing of this statement shall not be construed as an admission that any of the Reporting Persons is, for the purpose of 13(d) or 13(g) of the Act, the beneficial owner of any securities covered by this statement. Please note that the Reporting Persons do not have any voting control over any of the securities held by the separately managed account referenced herein. EXHIBIT A JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock (this "Agreement"), is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below that is named as a reporting person in such filing in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Joint Filing Agreement dated August 14, 2025, among Summit Partners Public Asset Management, LLC, Summit Partners, L.P., Summit Partners Concentrated Growth L/S Master Fund, L.P., Summit Partners Technology L/S Master Fund, L.P., Summit Partners Sustainable Opportunities L/S Fund Limited, Summit Partners Sustainable Opportunities L/S QP Fund, L.P., Summit Partners Sustainable Opportunities L/S Fund, L.P., Summit Partners Alydar GP, L.P., Summit Partners Alydar GP, LLC, Philip Furse, Timothy Albright, Robert MacAulay and Matthew Curtis. Dated: August 14, 2025 Summit Partners Public Asset Management, LLC Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, Authorized Person Summit Partners, L.P. Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, Authorized Person Summit Partners Concentrated Growth L/S Master Fund, L.P. Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, Authorized Person Summit Partners Technology L/S Master Fund, L.P. Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, Authorized Person Summit Partners Sustainable Opportunities L/S Fund Limited Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, Authorized Person Summit Partners Sustainable Opportunities L/S QP Fund, L.P. Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, Authorized Person Summit Partners Sustainable Opportunities L/S Fund, L.P. Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, Authorized Person Summit Partners Alydar GP, L.P. Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, Authorized Person Summit Partners Alydar GP, LLC Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, Authorized Person Philip Furse Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, POA for Philip Furse Timothy Albright Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, POA for Timothy Albright Robert MacAulay Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, POA for Robert MacAulay Matthew Curtis Signature: /s/ Adam H. Hennessey Name/Title: Adam H. Hennessey, POA for Matthew Curtis EXHIBIT B POWERS OF ATTORNEY Powers of Attorney, dated as of January 31, 2024, (incorporated herein by reference to Exhibit B to that certain Schedule 13G filed on January 31, 2024, with the Securities and Exchange Commission in connection with securities of Klaviyo, Inc.).

    Get the next $WGS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $WGS

    DatePrice TargetRatingAnalyst
    7/9/2025$110.00Overweight
    Piper Sandler
    5/15/2025$88.00Buy
    Guggenheim
    5/9/2025$80.00Hold → Buy
    Jefferies
    8/28/2024$34.00Equal Weight
    Wells Fargo
    7/10/2024$43.00Buy
    Craig Hallum
    6/3/2024$21.00Hold
    Jefferies
    More analyst ratings

    $WGS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by GeneDx Holdings Corp.

    SCHEDULE 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)

    8/14/25 12:33:25 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by GeneDx Holdings Corp.

    SCHEDULE 13G/A - GeneDx Holdings Corp. (0001818331) (Subject)

    8/6/25 12:01:29 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.

    SCHEDULE 13G - GeneDx Holdings Corp. (0001818331) (Subject)

    7/30/25 12:19:17 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on GeneDx with a new price target

    Piper Sandler initiated coverage of GeneDx with a rating of Overweight and set a new price target of $110.00

    7/9/25 8:30:02 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Guggenheim initiated coverage on GeneDx with a new price target

    Guggenheim initiated coverage of GeneDx with a rating of Buy and set a new price target of $88.00

    5/15/25 8:11:58 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx upgraded by Jefferies with a new price target

    Jefferies upgraded GeneDx from Hold to Buy and set a new price target of $80.00

    5/9/25 8:38:50 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $WGS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $WGS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    GeneDx to Participate in Upcoming Investor Conferences

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences: Canaccord Genuity's 45th Annual Growth Conference Boston, Massachusetts Fireside chat: Tuesday, August 12 at 8:00 a.m. ET 2025 Wells Fargo Healthcare Conference Boston, Massachusetts Fireside chat: Thursday, September 4 at 2:15 p.m. ET Morgan Stanley 23rd Annual Global Healthcare Conference New York, New York Fireside chat: Monday, September 8 at 8:30 a.m. ET Live and archived webcasts of the presentations will be available on the "Events" section of the GeneDx investor relations website at ir.

    8/6/25 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

    Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue Expanded adjusted gross margin to 71% and generated adjusted net income1 of $15.0 million for the second quarter 2025 Raised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue Announced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability Hosting conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved hea

    7/29/25 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025. Management will host a conference call that day to discuss second quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone

    7/10/25 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $3,007,997 worth of shares (50,000 units at $60.16) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/16/25 4:00:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Director Meister Keith A. bought $5,600,994 worth of shares (100,000 units at $56.01) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    5/12/25 7:46:55 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Casdin Capital, Llc bought $2,757,117 worth of shares (130,000 units at $21.21) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    6/5/24 8:45:06 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: Director Casdin Eli converted options into 12,924 shares, increasing direct ownership by 170% to 20,518 units (SEC Form 4)

    4/A - GeneDx Holdings Corp. (0001818331) (Issuer)

    8/7/25 7:41:01 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 753 shares and sold $40,860 worth of shares (388 units at $105.31), increasing direct ownership by 11% to 3,757 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    7/31/25 4:06:11 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Chief Executive Officer Stueland Katherine converted options into 3,874 shares and sold $226,838 worth of shares (2,154 units at $105.31), increasing direct ownership by 100% to 3,440 units (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    7/31/25 4:04:37 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Leadership Updates

    Live Leadership Updates

    View All

    GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

    Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More New Executive Leadership Positions Company for Growth and Scale GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team. As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program

    1/2/25 4:01:00 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary

    Veteran Legal Executive from Zoetis and Pfizer Joins GeneDx Executive Leadership Team to Lead Legal, Compliance and Policy Functions GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Heidi Chen as Chief Legal Officer, effective November 25, 2024. In her role, Heidi will report to Katherine Stueland, CEO and President, and will serve on the executive leadership team. With over 30 years of experience, Heidi will lead all legal, compliance, and policy functions at GeneDx and will provide strategic counsel on corporate governance, intellectual property, regulatory matters, federal policy, compliance and more.

    11/18/24 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    12/12/23 5:31:00 PM ET
    $EXAS
    $ILMN
    $LAB
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $WGS
    Financials

    Live finance-specific insights

    View All

    GeneDx Reports Second Quarter 2025 Financial Results and Business Highlights

    Reported second quarter 2025 revenues of $102.7 million with 69% year-over-year growth of exome and genome test revenue Expanded adjusted gross margin to 71% and generated adjusted net income1 of $15.0 million for the second quarter 2025 Raised guidance to deliver between $400 and $415 million in revenue with between 48% to 52% full year growth in exome and genome revenue Announced American Academy of Pediatrics (AAP) now recommends pediatricians use exome and genome testing as first-line for children with global developmental delay or intellectual disability Hosting conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved hea

    7/29/25 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx to Report Second Quarter 2025 Financial Results on Tuesday, July 29, 2025

    GeneDx (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today announced it will release financial results for the second quarter of 2025 before the market opens on Tuesday, July 29, 2025. Management will host a conference call that day to discuss second quarter 2025 financial and operating results at 8:30 a.m. Eastern Time. Conference Call Details Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the "Events" section of the GeneDx investor relations website at https://ir.genedx.com/. About GeneDx At GeneDx (NASDAQ:WGS), we believe that everyone

    7/10/25 8:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    GeneDx Reports First Quarter 2025 Financial Results and Business Highlights

    Reported first quarter 2025 revenues of $87.1 million with 62% year-over-year growth of exome and genome test revenue Generated first quarter 2025 adjusted net income1 of $7.7 million Announced plans to acquire Fabric Genomics Raised guidance to deliver between $360 and $375 million in revenue and reaffirmed outlook to deliver exome/genome volume and revenue growth of at least 30% in FY 2025 GeneDx to host conference call today at 8:30 a.m. ET GeneDx Holdings Corp. (NASDAQ:WGS), a leader in delivering improved health outcomes through genomic insights, today reported its financial results for the first quarter of 2025. "Healthcare is at an inflection point where integrating genomic ins

    4/30/25 6:30:00 AM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $WGS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/20/24 9:36:13 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/19/24 8:00:24 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    Amendment: SEC Form SC 13D/A filed by GeneDx Holdings Corp.

    SC 13D/A - GeneDx Holdings Corp. (0001818331) (Subject)

    11/8/24 5:23:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology